Información sobre la enfermedad por coronavirus 2019 (COVID-19) para profesionales sanitarios
Hidroxicloroquina/cloroquina:
- Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019 – JAMA Pediatrics
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 – NEJM
- Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis – The Lancet
- Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial – BMJ
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 – NEJM
- COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression – J Antimicrob Chemother
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial – Int J Antimicrob Ag
- Aminoquinolines Against Coronavirus Disease 2019 (COVID-19): Chloroquine or Hydroxychloroquine – Int J Antimicrob Ag
- Chloroquine for the 2019 novel coronavirus SARS-CoV-2 – Int J Antimicrob Ag
